

Ging-Yuek R Hsiung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6231925/publications.pdf>

Version: 2024-02-01

157
papers

13,117
citations

57681

46
h-index

28425

109
g-index

167
all docs

167
docs citations

167
times ranked

17910
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
2	Informant-based tools for assessment and monitoring of cognition, behavior, and function in neurocognitive disorders: Systematic review and report from a CCCDTD5 Working Group. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	2
3	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. <i>Cell Reports Medicine</i> , 2022, 3, 100607.	3.3	21
4	Differences in Motor Features of <i>C9orf72</i> , <i>MAPT</i> , or <i>GRN</i> Variant Carriers With Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2022, 99, .	1.5	5
5	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
6	Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12189.	1.2	9
7	Exploring the Contribution of Myelin Content in Normal Appearing White Matter to Cognitive Outcomes in Cerebral Small Vessel Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 91-101.	1.2	9
8	Left-Handed Man with Memory Complaints. , 2021, , 49-53.		0
9	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
10	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	0.7	10
11	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. <i>Cortex</i> , 2021, 139, 99-115.	1.1	12
12	Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 4001.	5.8	19
13	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
14	Coexistence of Multiple Sclerosis and Alzheimer Disease Pathology: A Case Series. <i>Journal of Neurology Research</i> , 2021, 11, 60-67.	0.2	2
15	FDG-PET in presymptomatic <i>C9orf72</i> mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 31, 102687.	1.4	16
16	Cardiovascular risk moderates the effect of aerobic exercise on executive functions in older adults with subcortical ischemic vascular cognitive impairment. <i>Scientific Reports</i> , 2021, 11, 19974.	1.6	6
17	Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab. <i>Canadian Geriatrics Journal</i> , 2021, 24, 373-378.	0.7	6
18	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. <i>Alzheimer's and Dementia</i> , 2020, 16, 11-21.	0.4	32

#	ARTICLE	IF	CITATIONS
19	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
20	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. <i>Alzheimer's and Dementia</i> , 2020, 16, 22-36.	0.4	32
21	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
22	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , 2020, 15, 57.	4.4	33
23	The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score. <i>Clinical Nuclear Medicine</i> , 2020, 45, 427-433.	0.7	12
24	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, 1115-1124.	0.4	11
25	An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid β 1-40 and 1-42 peptides in CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12036.		5
26	CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12057.	1.8	9
27	A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 12063.	1.6	11
28	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	1.6	4
29	Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer's Eye. <i>Frontiers in Neuroscience</i> , 2020, 14, 758.	1.4	42
30	Amyloid Deposits in the Retina of the Human Eye are Biomarkers of Two Different Diseases. , 2020, , .		0
31	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	2.8	19
32	Trehalose Inhibits A β Generation and Plaque Formation in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 3150-3157.	1.9	20
33	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. <i>Alzheimer's and Dementia</i> , 2020, 16, 118-130.	0.4	43
34	Utility of the global CDR [®] plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, 106-117.	0.4	81
35	Revised Self-Monitoring Scale. <i>Neurology</i> , 2020, 94, e2384-e2395.	1.5	23
36	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.3	56

#	ARTICLE	IF	CITATIONS
37	Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. <i>Frontiers in Neurology</i> , 2019, 10, 486.	1.1	33
38	Clinicopathologic correlations in a family with a <i>TBK1</i> mutation presenting as primary progressive aphasia and primary lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 568-575.	1.1	24
39	Generation of an induced pluripotent stem cell line (LUBCi001-A) from a presymptomatic individual carrying the R418X progranulin gene mutation. <i>Stem Cell Research</i> , 2019, 41, 101582.	0.3	1
40	New Perspective for Non-invasive Brain Stimulation Site Selection in Mild Cognitive Impairment: Based on Meta- and Functional Connectivity Analyses. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 228.	1.7	20
41	The Influence of Cerebrospinal Fluid Abnormalities and APOE 4 on PHF-Tau Protein: Evidence From Voxel Analysis and Graph Theory. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 208.	1.7	3
42	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14
43	Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers. <i>Frontiers in Computational Neuroscience</i> , 2019, 13, 72.	1.2	97
44	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	1.2	84
45	The Effect of Aerobic Exercise on White Matter Hyperintensity Progression May Vary by Sex. <i>Canadian Journal on Aging</i> , 2019, 38, 236-244.	0.6	18
46	Cerebral Amyloid- β^2 Deposition Is Associated with Impaired Gait Speed and Lower Extremity Function. <i>Journal of Alzheimer's Disease</i> , 2019, 71, S41-S49.	1.2	17
47	Genome-wide analyses as part of the international FTLTDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLTDP. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
48	THE ROLE OF S100B IN AEROBIC TRAINING EFFICACY IN OLDER ADULTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. <i>Innovation in Aging</i> , 2019, 3, S171-S172.	0.0	0
49	AEROBIC TRAINING, THE DEFAULT MODE NETWORK, AND COGNITION IN OLDER ADULTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. <i>Innovation in Aging</i> , 2019, 3, S55-S55.	0.0	0
50	The Use of Random Forests to Classify Amyloid Brain PET. <i>Clinical Nuclear Medicine</i> , 2019, 44, 784-788.	0.7	15
51	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 797-808.	1.2	12
52	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 232-238.	0.9	32
53	Prevalence of delusions in drug-naïve Alzheimer disease patients: A meta-analysis. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1287-1293.	1.3	7
54	Cardiovascular Risk Moderates Aerobic Training Efficacy on Executive Function in Older Adults. <i>Medicine and Science in Sports and Exercise</i> , 2019, 51, 550-550.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Study protocol for Vitality: a proof-of-concept randomised controlled trial of exercise training or complex mental and social activities to promote cognition in adults with chronic stroke. <i>BMJ Open</i> , 2018, 8, e021490.	0.8	14
56	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1591-1606.	1.7	21
57	Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 583-589.	1.2	5
58	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
59	The role of exercise in mitigating subcortical ischemic vascular cognitive impairment. <i>Journal of Neurochemistry</i> , 2018, 144, 582-594.	2.1	19
60	Detection of cognitive impairment using a machine-learning algorithm. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2939-2945.	1.0	18
61	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39
62	Prevalence of amyloid β 2 pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
63	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 102.	3.0	24
64	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. <i>NeuroImage: Clinical</i> , 2018, 18, 591-598.	1.4	26
65	16-Year Survival of the Canadian Collaborative Cohort of Related Dementias. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 367-374.	0.3	3
66	Drusen in the Peripheral Retina of the Alzheimer's Eye. <i>Current Alzheimer Research</i> , 2018, 15, 743-750.	0.7	24
67	Poster Presentations at the 9th Canadian Conference on Dementia (CCD) Toronto, November 2017. <i>Canadian Geriatrics Journal</i> , 2018, 21, 71-133.	0.7	0
68	Pharmacological Therapy for Apathy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 267-275.	0.3	28
69	The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 449-462.	1.2	18
70	Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial. <i>BMJ Open</i> , 2017, 7, e014387.	0.8	8
71	Sex Difference in Aerobic Exercise Efficacy to Improve Cognition in Older Adults with Vascular Cognitive Impairment: Secondary Analysis of a Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1397-1410.	1.2	55
72	Sex differences in the prevalence of genetic mutations in FTD and ALS. <i>Neurology</i> , 2017, 89, 1633-1642.	1.5	47

#	ARTICLE	IF	CITATIONS
73	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. <i>Neuron</i> , 2017, 95, 808-816.e9.	3.8	493
74	[P4418]: SEX DIFFERENCES IN THE PREVALENCE OF GENETIC MUTATIONS IN FTD AND ALS: A META-ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1491.	0.4	0
75	Cerebral Microbleeds: A Call for Standardized Advanced Neuroimaging. <i>American Journal of Neuroradiology</i> , 2017, 38, E90-E91.	1.2	0
76	Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment. <i>BMC Geriatrics</i> , 2017, 17, 133.	1.1	6
77	Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 46.	1.7	30
78	The Impact of Aerobic Exercise on Fronto-Parietal Network Connectivity and Its Relation to Mobility: An Exploratory Analysis of a 6-Month Randomized Controlled Trial. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 344.	1.0	27
79	Construction and Analysis of Weighted Brain Networks from SICE for the Study of Alzheimer's Disease. <i>Frontiers in Neuroinformatics</i> , 2017, 11, 19.	1.3	15
80	Clinical and neuropathological features of ALS/FTD with TIA1 mutations. <i>Acta Neuropathologica Communications</i> , 2017, 5, 96.	2.4	38
81	Neuropathological correlates of Corticobasal Syndrome. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, S4-S4.	0.3	0
82	The Association Between Obstructive Sleep Apnea and Alzheimer's Disease: A Meta-Analysis Perspective. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 78.	1.7	171
83	Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-O. <i>PLoS ONE</i> , 2016, 11, e0153878.	1.1	13
84	Risk of progression to dementia from MCI, how significant is the impact of depression? A sensitivity report. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1255-1257.	1.3	2
85	Neuropsychiatric symptoms in Alzheimer's disease (AD): How sensitive, how prevalent?. <i>Journal of Affective Disorders</i> , 2016, 201, 99-100.	2.0	1
86	Morphometricity as a measure of the neuroanatomical signature of a trait. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5749-56.	3.3	53
87	Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6535-E6544.	3.3	137
88	Microbleeds in Alzheimer's Disease: A Neuropsychological Overview and Meta-Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 753-759.	0.3	14
89	Aerobic exercise and vascular cognitive impairment. <i>Neurology</i> , 2016, 87, 2082-2090.	1.5	104
90	Prevalence of Brain Microbleeds in Alzheimer Disease: A Systematic Review and Meta-Analysis on the Influence of Neuroimaging Techniques. <i>American Journal of Neuroradiology</i> , 2016, 37, 215-222.	1.2	47

#	ARTICLE	IF	CITATIONS
91	Periventricular hyperintensities are associated with elevated cerebral amyloid. <i>Neurology</i> , 2016, 86, 535-543.	1.5	75
92	Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?. <i>Current Alzheimer Research</i> , 2016, 13, 750-763.	0.7	9
93	P3â€298: A randomized controlled trial of music therapy in managing behavioral symptoms in Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2015, 11, P749.	0.4	2
94	Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. <i>BMC Neurology</i> , 2015, 15, 197.	0.8	9
95	C-TOC (Cognitive Testing on Computer). <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 213-221.	0.6	10
96	P1-196: Patients with Alzheimer disease respond differently to familiar and unfamiliar music: An fMRI study. , 2015, 11, P424-P424.		1
97	The Prevalence of Depressive Symptoms in Frontotemporal Dementia: A Meta-Analysis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 257-271.	0.7	28
98	Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. <i>British Journal of Sports Medicine</i> , 2015, 49, 1343-1347.	3.1	15
99	A Voxel Based Morphometric Analysis of Longitudinal Cortical Gray Matter Changes in Progranulin Mutation Carriers At-Risk for Frontotemporal Dementia: Preliminary Study. <i>Dementia and Neurocognitive Disorders</i> , 2015, 14, 163.	0.4	2
100	Poster Presentations at the 8th Canadian Conference on Dementia (CCD), Ottawa, October 2015. <i>Canadian Geriatrics Journal</i> , 2015, 18, 250-300.	0.7	0
101	MicroRNAs targeting Nicastrin regulate A β production and are affected by target site polymorphisms. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 67.	1.4	24
102	Nitrous Oxide (N ₂ O)-Induced Acute Psychosis. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 672-674.	0.3	17
103	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. <i>Molecular Neurodegeneration</i> , 2014, 9, 38.	4.4	63
104	Early Neuropsychological Characteristics of Progranulin Mutation Carriers. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 694-703.	1.2	21
105	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. <i>Acta Neuropathologica</i> , 2014, 127, 397-406.	3.9	133
106	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	1.5	74
107	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
108	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. <i>Neurobiology of Aging</i> , 2014, 35, 936.e5-936.e12.	1.5	47

#	ARTICLE	IF	CITATIONS
109	Effect of White Matter Hyperintensity on Medial Temporal Lobe Atrophy in Alzheimer's Disease. <i>European Neurology</i> , 2013, 69, 229-235.	0.6	17
110	Early-onset dementias: diagnostic and etiological considerations. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S7.	3.0	47
111	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S8.	3.0	17
112	Genome-wide scan of healthy human connectome discovers <i>SPON1</i> gene variant influencing dementia severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4768-4773.	3.3	141
113	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
114	<i>C9ORF72</i> repeat expansions in cases with previously identified pathogenic mutations. <i>Neurology</i> , 2013, 81, 1332-1341.	1.5	84
115	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. <i>Neurology</i> , 2013, 81, 1322-1331.	1.5	60
116	<i>TMEM106B</i> p.T185S regulates <i>TMEM106B</i> protein levels: implications for frontotemporal dementia. <i>Journal of Neurochemistry</i> , 2013, 126, 781-791.	2.1	87
117	Early-Onset Familial Alzheimer's Disease (EOFAD). <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 436-445.	0.3	160
118	Clinical and pathological features of familial frontotemporal dementia caused by <i>C9ORF72</i> mutation on chromosome 9p. <i>Brain</i> , 2012, 135, 709-722.	3.7	201
119	Association of common genetic variants in <i>GPCPD1</i> with scaling of visual cortical surface area in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3985-3990.	3.3	50
120	Multiple Pathologies are Common in Alzheimer Patients in Clinical Trials. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 592-599.	0.3	28
121	Rapidly Progressive Dementia in a Chinese Patient due to <i>C9ORF72</i> Mutation. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 676-677.	0.3	8
122	Stay the course "is it justified?". <i>Lancet</i> , The, 2012, 379, 220.	6.3	6
123	Prevalence of Mild Cognitive Impairment and Its Subtypes in the Mexican Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 271-281.	0.7	46
124	A voxel-based morphometric study of cortical gray matter volume changes in Alzheimer's disease with white matter hyperintensities. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1506-1510.	0.8	18
125	Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer's Disease with Comorbid Depression. <i>Drugs and Aging</i> , 2012, 29, 793-806.	1.3	79
126	rs5848 polymorphism and serum progranulin level. <i>Journal of the Neurological Sciences</i> , 2011, 300, 28-32.	0.3	77

#	ARTICLE	IF	CITATIONS
127	Voxel-based morphometric study of brain volume changes in patients with Alzheimer's disease assessed according to the Clinical Dementia Rating score. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 916-921.	0.8	22
128	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. <i>Neuron</i> , 2011, 72, 245-256.	3.8	4,176
129	Challenges moving forward with economic evaluations of exercise intervention strategies aimed at combating cognitive impairment and dementia. <i>British Journal of Sports Medicine</i> , 2011, 45, 470-472.	3.1	13
130	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 196-203.	0.9	170
131	A Novel PS1 Gene Mutation in a Large Aboriginal Kindred. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 359-364.	0.3	9
132	Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. <i>BMC Neurology</i> , 2010, 10, 14.	0.8	50
133	A commonly carried allele of the obesity-related <i>FTO</i> gene is associated with reduced brain volume in the healthy elderly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8404-8409.	3.3	227
134	An exploration of cognitive subgroups in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 233-243.	1.2	35
135	Sex-dependent association of common variants of microcephaly genes with brain structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 384-388.	3.3	118
136	Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional executive network function in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10256-10261.	3.3	215
137	Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 553.	1.0	14
138	Subregional neuroanatomical change as a biomarker for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20954-20959.	3.3	198
139	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1174-1176.	1.3	6
140	Neuropsychiatric Symptom Clusters and Functional Disability in Cognitively-Impaired-Not-Demented Individuals. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 136-144.	0.6	25
141	Pharmacological treatment in moderate-to-severe Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2575-2582.	0.9	21
142	Transition from Cognitively Impaired Not Demented to Alzheimer's Disease: An Analysis of Changes in Functional Abilities in a Dementia Clinic Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 483-490.	0.7	26
143	Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 45-53.	4.9	443
144	Behavioural Measures in Frontotemporal Lobar Dementia and Other Dementias: The Utility of the Frontal Behavioural Inventory and the Neuropsychiatric Inventory in a National Cohort Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 406-415.	0.7	31

#	ARTICLE	IF	CITATIONS
145	Genetics and dementia: Risk factors, diagnosis, and management. <i>Alzheimer's and Dementia</i> , 2007, 3, 418-427.	0.4	35
146	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C>T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , The, 2007, 6, 857-868.	4.9	199
147	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , 2006, 129, 3081-3090.	3.7	291
148	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2006, 15, 2988-3001.	1.4	529
149	Outcomes of Cognitively Impaired Not Demented at 2 Years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 413-420.	0.7	53
150	Dropouts and refusals in observational studies. <i>Neurology</i> , 2006, 67, S17-20.	1.5	13
151	Cholesterol in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2005, 4, 841-852.	4.9	292
152	Apolipoprotein E ϵ 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. <i>Cmaj</i> , 2004, 171, 863-867.	0.9	144
153	A dyslexia susceptibility locus (DYX7) linked to dopamine D4 receptor (DRD4) region on chromosome 11p15.5. <i>American Journal of Medical Genetics Part A</i> , 2004, 125B, 112-119.	2.4	55
154	A Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD): Study Methods and Baseline Results. <i>Neuroepidemiology</i> , 2003, 22, 265-274.	1.1	127
155	A 67-year-old woman with Parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 2001, 28, 150-154.	0.3	0
156	Moyamoya Syndrome in a Patient With Congenital Human Immunodeficiency Virus Infection. <i>Journal of Child Neurology</i> , 1999, 14, 268-270.	0.7	29
157	Young man with progressive speech impairment and weakness. , 0, , 105-114.		0